FindTrial
Sign In

A Phase 1b/2a Open-Label Dose-Finding Followed by Randomized, Double-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TGD001 in Patients with Acute Ischemic Stroke

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522455-26-00
Acronym
TG1-CL-201
Enrollment
80
Registered
2025-10-31
Start date
2025-12-17
Completion date
Unknown
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

Symptomatic intracranial hemorrhage (sICH), Treatment emergent adverse events (TEAEs)

Interventions

DRUGSODIUM CHLORIDE SOLUTION 0.9%

Sponsors

TargED Biopharmaceuticals B.V.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Symptomatic intracranial hemorrhage (sICH), Treatment emergent adverse events (TEAEs)—

Countries

Germany, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026